MannKind Corporation (MNKD) |
|
4.695 -0.125 (-2.59%)
|
12-05 13:06 |
|
Open: |
4.81 |
Pre. Close: |
4.82 |
|
High:
|
4.81 |
Low:
|
4.64 |
|
Volume:
|
1,047,024 |
Market Cap:
|
1,236(M) |
|
|
|
Technical analysis |
as of: 2022-12-05 12:50:57 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 5.65 One year: 6.6 |
| Support: |
Support1: 3.91  Support2: 3.33 |
| Resistance: |
Resistance1: 4.84 Resistance2: 5.65 |
| Pivot: |
4.43 |
| Moving Average: |
MA(5): 4.65 MA(20): 4.32
MA(100): 3.72 MA(250): 3.74 |
| MACD: |
MACD(12,26): 0.2 Signal(9): 0.2 |
| Stochastic oscillator: |
%K(14,3): 90.9 %D(3): 92.9 |
| RSI: |
RSI(14): 68.2 |
| 52-week: |
High: 4.86 Low: 2.49 |
| Average Vol(K): |
3-Month: 4,538 (K) 10-Days: 3,204 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MNKD ] has closed below upper band by 16.0%. Bollinger Bands are 9.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.84 - 4.87 |
4.87 - 4.89 |
|
Low:
|
4.48 - 4.51 |
4.51 - 4.53 |
|
Close:
|
4.78 - 4.82 |
4.82 - 4.86 |
|
Company Description |
|
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California. |
Headline News |
Mon, 05 Dec 2022
MannKind's Return On Capital Employed Overview - MannKind (NASDAQ:MNKD) - Benzinga
Tue, 22 Nov 2022
MannKind Is Poised To Turn A Profit And Shares Could Get Cheaper (NASDAQ:MNKD) - Seeking Alpha
Mon, 21 Nov 2022
Should You Add MannKind Corp (MNKD) Stock to Your Portfolio Monday? - InvestorsObserver
Tue, 15 Nov 2022
Official: Mannkind worker hurt after equipment fire in Danbury - Danbury News Times
Thu, 10 Nov 2022
MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting - GlobeNewswire
Wed, 09 Nov 2022
Is MannKind Corp (MNKD) a Stock to Watch After Gaining 16.52% This Week? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
263 (M) |
| Shares Float |
259 (M) |
|
% Held by Insiders
|
6.1 (%) |
|
% Held by Institutions
|
50.3 (%) |
|
Shares Short
|
35,040 (K) |
|
Shares Short P.Month
|
35,330 (K) |
Stock Financials |
|
EPS
|
-0.38 |
|
EPS Est Next Qtl
|
-0.19 |
|
EPS Est This Year
|
-0.92 |
|
EPS Est Next Year
|
-0.76 |
|
Book Value (p.s.)
|
-0.9 |
|
Profit Margin (%)
|
-128 |
|
Operating Margin (%)
|
-111.7 |
|
Return on Assets (ttm)
|
-20 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
47.7 |
|
Gross Profit (p.s.)
|
0.13 |
|
Sales Per Share
|
0.28 |
|
EBITDA (p.s.)
|
-0.31 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-91 (M) |
|
Levered Free Cash Flow
|
-86 (M) |
Stock Valuations |
|
PE Ratio
|
-12.55 |
|
PEG Ratio
|
-0.4 |
|
Price to Book value
|
-5.23 |
|
Price to Sales
|
16.24 |
|
Price to Cash Flow
|
-13.67 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2017-03-02 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
